Regeneron ended clinical development of bbT369, a dual‑targeting CAR‑T acquired with 2seventy bio, and halted enrollment in the dose‑escalation lymphoma study before advancing to phase 2. The company attributed the decision to a strategic portfolio review and said no further development is planned for bbT369. Regeneron emphasized the move does not alter its broader cell therapy strategy, but the decision follows recent industry pullbacks and raises questions about the commercial and clinical risks of complex cell‑therapy assets.